Professional Documents
Culture Documents
Clinical Study
The Effect of Artichoke Leaf Extract on Alanine
Aminotransferase and Aspartate Aminotransferase in
the Patients with Nonalcoholic Steatohepatitis
Copyright © 2016 Vajiheh Rangboo et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. Based on recent basic and clinical investigations, the extract of artichoke (Cynara scolymus) leaf has been revealed to be
used for hepatoprotective and cholesterol reducing purposes. We aimed to assess the therapeutic effects of artichoke on biochemical
and liver biomarkers in patients with nonalcoholic steatohepatitis (NASH). Methods. In a randomized double blind clinical trial,
60 consecutive patients suffering NASH were randomly assigned to receive Cynara scolymus extract (as 6 tablets per day consisting
of 2700 mg extract of the herb) as the intervention group or placebo as the control group for two months. Results. Comparing
changes in study markers following interventions showed improvement in liver enzymes. The levels of triglycerides and cholesterol
were significantly reduced in the group treated with Cynara scolymus when compared to placebo group. To compare the role of
Cynara scolymus use with placebo in changes in study parameters, multivariate linear regression models were employed indicating
higher improvement in liver enzymes and also lipid profile particularly triglycerides and total cholesterol following administration
of Cynara scolymus in comparison with placebo use. Conclusion. This study sheds light on the potential hepatoprotective activity
and hypolipidemic effect of Cynara scolymus in management of NASH. This clinical trial is registered in the IRCT, Iranian Registry
of Clinical Trials, by number IRCT2014070218321N1.
1. Introduction In this regard, the best treatment approaches for this phe-
nomenon include weight loss, changes in dietary regimens,
Nonalcoholic fatty liver disease (NAFLD) refers to a wide and lifestyle modifications. Also, in cases with documented
spectrum of disorders characterized by fatty infiltration in hyperlipidemia or diabetes, use of insulin sensitizing and
the liver and steatosis [1]. By developing oxidative stress, lipid lowering drugs can be also considered [5]. However,
hepatocellular inflammation, and steatosis, the term was since NASH is a multifactorial disorder, single target based
replaced by nonalcoholic steatohepatitis (NASH) that may therapy has limited implications. Hence, the use of herbal
culminate in cirrhosis and hepatocellular carcinoma [2, 3]. medicine approach can be a promising alternative due to its
Within the last decade, prevalence of NASH has interestingly multipronged mechanisms of action [6–8].
doubled especially in the Middle East, Far East, Africa, the Artichoke (Cynara scolymus) is a plant frequently grown
Caribbean, and Latin America due to its close association in Mediterranean countries that is rich in natural antioxidants
with lifestyle disorders such as diabetes and obesity [4]. and thus is used as a herbal drug [9]. Based on recent
2 International Journal of Hepatology
basic and clinical investigations, the extract of artichoke 2.3. Measurement of Biomarkers. Serum alanine transam-
leaf has been revealed to be used for hepatoprotective [10– inase (ALT) and aspartate transaminase (AST) activity
12], antimicrobial [13], and cholesterol reducing purposes was estimated colorimetrically using an especial kit (Pars
[14]. Azmoon company, Iran) according to the method of Reitman
Artichoke has been found to decrease the production of and Frankel [17]. Serum cholesterol (Chol) concentration
reactive oxygen species, the oxidation of low-density lipopro- was determined colorimetrically using an especial kit (Pars
teins [15], lipid peroxidation [11], and protein oxidation and Man company, Iran) according to the method of Allain et
increase the activity of glutathione peroxidase [16]. In this al. [18]. Serum LDL-cholesterol (LDL) concentration was
regard, it seems that the use of this herb may be promising to assayed colorimetrically using an especial kit (Pars Azmoon
treat NASH. The present study aimed to assess the therapeutic company, Iran) according to the method of Assmann et
effects of artichoke on biochemical and liver biomarkers in al. [19]. Serum HDL-cholesterol (HDL) concentration was
patients with NASH.
measured colorimetrically using an especial kit (Pars Man
company, Iran) according to the method of Lopez-Virella
2. Subjects and Methods et al. [20]. Serum triglycerides (TG) level was determined
colorimetrically using an especial kit (Pars Azmoon com-
2.1. Study Population. In a randomized double blind clinical pany, Iran) according to the method of Fassati and Prencipe
trial, 60 consecutive patients who suffered NASH (based on [21]. The biomarkers were measured at the two time points:
changes in liver enzymes and sonographic evidences) were admission time and 2 months after the initial assessment
included in the study. The main inclusion criteria were ele- (completing treatment protocols).
vation of liver enzymes (>30 𝜇/L), any evidences of fatty liver
in abdominal sonography, and the existence of at least one
2.4. Statistical Analysis. Results were presented as mean ±
of these characteristics: total cholesterol > 200 mg/dL, high
standard deviation (SD). Continuous variables were com-
density lipoprotein (HDL) < 40 mg/dL for men and <50 mg/
pared using 𝑡-test or nonparametric Mann-Whitney 𝑈 test.
dL for women, serum triglycerides level > 150 mg/dL, fasting
blood sugar > 100 mg/dL, obesity defined as body mass index The changes in study biomarkers after interventions were
assessed using the Paired 𝑡-test or nonparametric Wilcoxon
> 30 kg/m2 , or blood pressure > 130/85 mmHg. In this regard,
the main exclusion criteria were daily alcohol consumption, test. The multivariate linear regression analysis was used
diabetes mellitus type I, the existence of concomitant liver for assessing study outcomes following different employed
diseases such as hepatitis B or C, autoimmune hepatitis, protocols as follows. First, the baseline variables as probable
Wilson, hemochromatosis, alpha-1 antitrypsin deficiency, or confounders with a 𝑃 value <0.20 in univariate analyses
biliary obstruction, the use of vitamin C, livergol, hepatotoxic were taken in a multivariate logistic regression model to
drugs, NASH inducing drugs such as amiodarone, calcium- assess the difference between the treatment groups receiving
channel blockers, or tamoxifen, pregnancy or breastfeeding, Cynara scolymus extract or placebo with the presence of
sensitivity to artichoke species, or any life-threatening disor- these confounders. For the statistical analysis, the statistical
ders. software SPSS version 21.0 for windows (SPSS Inc., Chicago,
The two groups were matched in terms of sex distribution IL) was used.
(21 male and 9 female in both groups) and mean age (47.27 ±
8.12 years in intervention group and 49.83 ± 12.79 years in 3. Results
placebo group, 𝑃 = 0.357). The two groups were also similar
in other baseline characteristics including weight, levels of As shown in Table 1, following administration of Cynara
liver enzymes, lipid profile, and fasting blood sugar on initial scolymus, significant reduction was observed in mean weight,
assessment. as well as in serum levels of ALT, AST, blood sugar, total
cholesterol, LDL, and triglycerides. Also, mean systolic blood
2.2. Study Intervention. The baseline characteristics of pressure was significantly reduced using Cynara scolymus. In
patients were collected by interviewing and the study ques- contrast, using placebo resulted in significant reduction in
tionnaires were recorded. The patients were then randomly mean weight, as well as in serum levels of ALT and AST;
assigned to receive Cynara scolymus extract (as 6 tablets per however, among other biomarkers, blood sugar and lipid
day consisting of 2700 mg extract of the herb prepared in profile remained unchanged. Comparing changes in study
Dineh company, Qazvin, Iran) as the intervention group markers following interventions showed the changes in liver
or placebo as the control group for two months (placebo enzymes, and also levels of triglycerides and cholesterol were
was prepared from the same ingredient as treatment except significantly more in group treated with Cynara scolymus
Cynara scolymus extract). The randomization was done when compared to placebo group (Table 2). To compare
using computer generated random number tables. Both the role of Cynara scolymus use with placebo in changes
groups were advised to maintain regular physical activity in study parameters, multivariate linear regression models
(20 min walking within 5 days a week) and an appropriate were employed (Table 2) indicating higher improvement in
dietary regimen (calculated based on patients’ weight, height, liver enzymes and also lipid profiles of triglycerides and total
age, and percentage of activity using the Mifflin formula to cholesterol following administration of Cynara scolymus in
gradually reduce body weight). comparison with placebo use.
International Journal of Hepatology 3
Table 2: Multivariate linear regression models for determining the role of Cynara scolymus use on changes in liver enzymes and lipid profile.
improvement of lipid profile was significantly observed in drug. Another strength of the current study was to assess the
the group receiving Cynara scolymus extract not in placebo simultaneous changes in liver enzymes, blood sugar, and lipid
group. These effects could be attributed to active ingredi- profile. This concomitant assessment is important because the
ents in Cynara scolymus extract which are known as caf- central role of liver leads to metabolic pathways regulating
feoylquinic acid derivatives (cynarin and chlorogenic acid). the level of these metabolic biomarkers. However, our study
Some previous studies showed that these compounds can had some potential limitations including small sample size
reduce cholesterol by inhibiting HMG-COA reductase and leading to partially low study power as well as ignoring other
having a hypolipidemic influence lowering blood cholesterol baseline clinical and pharmacological confounders affecting
[26]. the employed regression models used for assessing the effects
Our result on hypocholesterolemic effect of Cynara scoly- of artichoke on biochemical and liver biomarkers in NASH.
mus extract is in agreement with Pittler et al. [35]. Some
studies suggest that Cynara scolymus extract reduces blood 5. Conclusion
lipids by directly influencing biosynthesis of cholesterol and
also by production and secretion of bile from the liver [36, 37]. In conclusion, the current study sheds light on the potential
Reduction in triglycerides level is attributed to improvement role of Cynara scolymus in management of NASH. The active
in glycemic control and reduction of glucose instead of constituents of this herb such as flavonoids and caffeoylquinic
fat. Acetyl COA yield from pyruvic acid enters Krebs cycle acid may be responsible for this effect. These compounds
and leads to metabolism of glucose completely instead of have been proven to have hepatoprotective activity and
triglycerides biosynthesis. hypolipidemic effect.
In present study improvement in fasting blood sugar was
significantly observed in group receiving Cynara scolymus
extract not in placebo group. This beneficial effect could be
Ethical Approval
attributed to high antioxidant capacity of this herb. Phenolic The protocol was approved by the Research Council and
compounds, specially, such as caffeic acid and flavonoids, are Ethical Committee of Qazvin University of Medical Sciences,
representative of this effect. no. D28/20/7929.
Another mechanism for reducing glucose level by Cynara
scolymus extract is affecting glucose absorption. Antioxidant
compounds delay depletion of stomach and bowels and Consent
they inhibited 𝛼-amylase and 𝛼-glucosidase enzymes in Consent was obtained from each patient. They could quit
bowels and blocked glucose transportation to blood. On the the study freely. All participants provided informed written
other hand antioxidants have insulin-like effect and increase consent.
glucose absorption in peripheral tissue. Another probable
mechanism is influencing 𝛽-cells, repairing damage cells, and
stimulating these cells to secrete insulin. Studies show that Competing Interests
chlorogenic acid has antidiabetic effect [38, 39] and reduction The authors have no competing interests.
glucose by reason of this compound.
Another point of this study was the parallel improvement
in liver enzymes and also lipid profile by administrating
Acknowledgments
Cynara scolymus that was not simultaneously in placebo The authors would like to thank Children Growth Research
group. Cholesterol metabolism is associated with liver fat Center, Qazvin University of Medical Sciences, Qazvin, Iran,
content independent of body weight, implying that the and Deputy of Research, Qazvin University of Medical and
more the fat the liver contains, the higher the cholesterol Health Sciences, Qazvin, Iran, for financial support (Grant
synthesis is [40]. Cellular cholesterol synthesis is regulated no. D.44.7929). Thanks are due to the mothers who partic-
by activation of membrane bound transcription factors, des- ipated in their study. They would also like to thank the health
ignated sterol regulatory element-binding proteins (SREBPs) care staff for cooperation in collecting the data and thank
which are the most abundant in the liver [41], and the Dineh company for providing the extract of artichoke leaf and
excess of cellular cholesterol is esterified by the acyl CoA- placebo.
cholesterol acyltransferase (ACAT) [42]. The high level of
cholesterol synthesis and the increased SREBP-2 activity have
paradoxically been shown in subjects with NASH [43]. It is References
thus suggested that the effects of Cynara scolymus may appear [1] N. Chalasani, Z. Younossi, J. E. Lavine et al., “The diagnosis
by inducing and involving these metabolic pathways in the and management of non-alcoholic fatty liver disease: practice
liver. guideline by the American Gastroenterological Association,
The main strength of the study was to shed light on American Association for the Study of Liver Diseases, and
the potential role of artichoke on biochemical and liver American College of Gastroenterology,” Gastroenterology, vol.
biomarkers in patients with NASH in a controlled trial. 142, no. 7, pp. 1592–1609, 2012.
Although, in previous studies, the role of this herb to treat [2] J. K. Dyson, Q. M. Anstee, and S. McPherson, “Non-alcoholic
NASH has been assessed, a few studies focused directly on the fatty liver disease: a practical approach to treatment,” Frontline
improvement of liver enzymes via administrating this herbal Gastroenterology, vol. 5, no. 4, pp. 277–286, 2014.
International Journal of Hepatology 5
[3] M. V. Machado and H. Cortez-Pinto, “Non-alcoholic fatty liver [19] G. Assmann, H.-U. Jabs, U. Kohnert, W. Nolte, and H.
disease: what the clinician needs to know,” World Journal of Schriewer, “LDL-cholesterol determination in blood serum
Gastroenterology, vol. 20, no. 36, pp. 12956–12980, 2014. following precipitation of LDL with polyvinylsulfate,” Clinica
[4] R. L. Corrado, D. M. Torres, and S. A. Harrison, “Review of Chimica Acta, vol. 140, no. 1, pp. 77–83, 1984.
treatment options for nonalcoholic fatty liver disease,” Medical [20] M. F. Lopez-Virella, P. Stone, S. Elli, and J. A. Golwell, “Choles-
Clinics of North America, vol. 98, no. 1, pp. 55–72, 2014. terol determination in HDL-chol separated by three different
[5] A. Eguchi, D. Povero, N. Alkhouri, and A. E. Feldstein, “Novel methods,” Clinical Chemistry, vol. 23, no. 5, pp. 882–884, 1977.
therapeutic targets for nonalcoholic fatty liver disease,” Expert [21] P. Fossati and L. Prencipe, “Serum triglycerides determined
Opinion on Therapeutic Targets, vol. 17, no. 7, pp. 773–779, 2013. colorimetrically with an enzyme that produces hydrogen per-
[6] P. Uhl, G. Fricker, U. Haberkorn, and W. Mier, “Current status in oxide,” Clinical Chemistry, vol. 28, no. 10, pp. 2077–2080, 1982.
the therapy of liver diseases,” International Journal of Molecular [22] S. R. Naik and V. S. Panda, “Antioxidant and hepatoprotective
Sciences, vol. 15, no. 5, pp. 7500–7512, 2014. effects of Ginkgo biloba phytosomes in carbon tetrachloride-
[7] M. Mouzaki and J. Allard, “Non-alcoholic steatohepatitis: the induced liver injury in rodents,” Liver International, vol. 27, no.
therapeutic challenge of a global epidemic,” Annals of Gastroen- 3, pp. 393–399, 2007.
terology, vol. 25, no. 3, pp. 207–217, 2012. [23] E. Azzini, R. Bugianesi, F. Romano et al., “Absorption and
metabolism of bioactive molecules after oral consumption of
[8] R. Jadeja, R. V. Devkar, and S. Nammi, “Herbal medicines for
cooked edible heads of Cynara scolymus L. (Cultivar Violetto di
the treatment of nonalcoholic steatohepatitis: current scenario
Provenza) in human subjects: a pilot study,” The British Journal
and future prospects,” Evidence-Based Complementary and
of Nutrition, vol. 97, no. 5, pp. 963–969, 2007.
Alternative Medicine, vol. 2014, Article ID 648308, 18 pages,
2014. [24] S. M. Wittemer, M. Ploch, T. Windeck et al., “Bioavailability
and pharmacokinetics of caffeoylquinic acids and flavonoids
[9] N. Mulinacci, D. Prucher, M. Peruzzi et al., “Commercial
after oral administration of Artichoke leaf extracts in humans,”
and laboratory extracts from artichoke leaves: estimation of
Phytomedicine, vol. 12, no. 1-2, pp. 28–38, 2005.
caffeoyl esters and flavonoidic compounds content,” Journal of
Pharmaceutical and Biomedical Analysis, vol. 34, no. 2, pp. 349– [25] K. Schütz, D. Kammerer, R. Carle, and A. Schieber, “Identifi-
357, 2004. cation and quantification of caffeoylquinic acids and flavonoids
from artichoke (Cynara scolymus L.) heads, juice, and pomace
[10] A. Y. Leung and S. Foster, Encyclopedia of Common Natural by HPLC-DAD-ESI/MSn,” Journal of Agricultural and Food
Ingredients Used in Food. Drugs and Cosmetics, John Wiley & Chemistry, vol. 52, no. 13, pp. 4090–4096, 2004.
Sons, New York, NY, USA, 2nd edition, 1996.
[26] R. Gebhardt, “Inhibition of cholesterol biosynthesis in primary
[11] C. A. Newall, L. A. Anderson, and J. D. Phillipson, Herbal cultured rat hepatocytes by artichoke (Cynara scolymus L)
Medicines: A Guide for Health-Care Professionals, The Pharma- extracts,” Journal of Pharmacology and Experimental Therapeu-
ceutical Press, London, UK, 1996. tics, vol. 286, no. 3, pp. 1122–1128, 1998.
[12] E. Speroni, R. Cervellati, P. Govoni, S. Guizzardi, C. Renzulli, [27] J. Vaya and M. Aviram, “Nutritional antioxidants mechanisms
and M. C. Guerra, “Efficacy of different Cynara scolymus prepa- of action, analyses of activities and medical applications,” Cur-
rations on liver complaints,” Journal of Ethnopharmacology, vol. rent Medicinal Chemistry-Immunology, Endocrine & Metabolic
86, no. 2-3, pp. 203–211, 2003. Agents, vol. 1, no. 1, pp. 99–117, 2001.
[13] X. Zhu, H. Zhang, and R. Lo, “Phenolic compounds from the [28] I. Urquiaga and F. Leighton, “Plant polyphenol antioxidants and
leaf extract of artichoke (Cynara scolymus L.) and their antimi- oxidative stress,” Biological Research, vol. 33, no. 2, pp. 55–64,
crobial activities,” Journal of Agricultural and Food Chemistry, 2000.
vol. 52, no. 24, pp. 7272–7278, 2004.
[29] E. Heidarian, Y. Soofiniya, and R. Hajihosseini, “The effect of
[14] Z. Küskü-Kiraz, G. Mehmetçik, S. Dogru-Abbasoglu, and M. aerial part of Cynara scolymus extract on the hyperlipidemia,
Uysal, “Artichoke leaf extract reduces oxidative stress and plasma antioxidant capacity, and superoxide dismutase activity
lipoprotein dyshomeostasis in rats fed on high cholesterol diet,” in diabetic rats,” Journal of Shahrekord University of Medical
Phytotherapy Research, vol. 24, no. 4, pp. 565–570, 2010. Sciences, vol. 13, no. 5, pp. 1–10, 2013.
[15] D. Zapolska-Downar, A. Zapolski-Downar, M. Naruszewicz, [30] N. S. Metwally, T. E. Kholeif, K. Z. Ghanem, A. R. H. Farrag, N.
A. Siennicka, B. Krasnodbska, and B. Kolodziej, “Protective M. Ammar, and A. H. Z. Abdel-Hamid, “The protective effects
properties of artichoke (Cynara scolymus) against oxidative of fish oil and artichoke on hepatocellular carcinoma in rats,”
stress induced in cultured endothelial cells and monocytes,” Life European Review for Medical and Pharmacological Sciences, vol.
Sciences, vol. 71, no. 24, pp. 2897–2908, 2002. 15, no. 12, pp. 1429–1444, 2011.
[16] A. Jiménez-Escrig, L. O. Dragsted, B. Daneshvar, R. Pulido, [31] G. Mehmetçik, G. Özdemirler, N. Koçak-Toker, U. Çevikbaş,
and F. Saura-Calixto, “In vitro antioxidant activities of edible and M. Uysal, “Effect of pretreatment with artichoke extract on
artichoke (Cynara scolymus L.) and effect on biomarkers of carbon tetrachloride-induced liver injury and oxidative stress,”
antioxidants in rats,” Journal of Agricultural and Food Chemistry, Experimental and Toxicologic Pathology, vol. 60, no. 6, pp. 475–
vol. 51, no. 18, pp. 5540–5545, 2003. 480, 2008.
[17] S. Reitman and S. Frankel, “Colorimetric method for the deter- [32] S. Miccadei, D. D. Venere, A. Cardinali et al., “Antioxidative and
mination of serum glutamic oxalacetic and glutamic pyruvic apoptotic properties of polyphenolic extracts from edible part of
transaminases,” American Journal of Clinical Pathology, vol. 28, artichoke (Cynara scolymus L.) on cultured rat hepatocytes and
no. 1, pp. 56–63, 1957. on human hepatoma cells,” Nutrition and Cancer, vol. 60, no. 2,
[18] C. C. Allain, L. S. Poon, C. S. Chan, W. Richmond, and P. C. Fu, pp. 276–283, 2008.
“Enzymatic determination of total serum cholesterol,” Clinical [33] M. Safaa, A. Hanaa, F. Abdel, A. Nahila, and S. Abdelaaty,
Chemistry, vol. 20, pp. 470–475, 1974. “Cynara scolymus for relieving on nonalcoholic steatohepatitis
6 International Journal of Hepatology
INFLAMMATION
BioMed
PPAR Research
Hindawi Publishing Corporation
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014
Journal of
Obesity
Evidence-Based
Journal of Stem Cells Complementary and Journal of
Ophthalmology
Hindawi Publishing Corporation
International
Hindawi Publishing Corporation
Alternative Medicine
Hindawi Publishing Corporation Hindawi Publishing Corporation
Oncology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014
Parkinson’s
Disease
Computational and
Mathematical Methods
in Medicine
Behavioural
Neurology
AIDS
Research and Treatment
Oxidative Medicine and
Cellular Longevity
Hindawi Publishing Corporation Hindawi Publishing Corporation Hindawi Publishing Corporation Hindawi Publishing Corporation Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014 http://www.hindawi.com Volume 2014